PharmaVoice

JULY 18, 2023

A former WHO epidemiologist is applying lessons learned during the Ebola epidemic to her work leading a company at the forefront of women’s health: the reproductive microbiome.

Leads 130

Leads 130

Fierce Pharma

OCTOBER 18, 2023

Back in 2018, Irish authorities hit Shire with a €398 million charge tied to that company’s rejection of AbbVie’s takeover bid in 2014. . | Takeda will pay €130 million (about $137 million) to resolve a tax assessment from the Irish Revenue Commissioners, the company said Wednesday. Takeda ultimately purchased Shire for $62 billion in 2019.

219

219

Fierce Pharma

AUGUST 28, 2023

With seven posters and nine presentations on Farxiga over the weekend at the European Society of Cardiology (ESC) scientific sessions in Amsterdam, AstraZeneca made it clear that it has lots to say | As AstraZeneca's Farxiga has added four indications over the last five years—on top of its initial 2014 approval for Type 2 diabetes—its spillover (..)

230

230

PharmExec

NOVEMBER 2, 2022

November 3rd 2022 9 am CT |10 am ET | 2 pm GMT | 3pm CET The way clinical trials are conducted in the European Union is undergoing major changes with (EU) No 536/2014.

52

52

World of DTC Marketing

JANUARY 10, 2022

Data were mainly accessible for smaller firms, effects in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products approved between 2014 and 2018. According to the study in JAMA “the FDA approved 355 new drugs and biologics over the study period.

Food and Drug Administration 213

Food and Drug Administration Pharma Marketing Food 213

World of DTC Marketing

JANUARY 4, 2022

In 2014, cancer patients paid $4 billion out-of-pocket for cancer treatment. Cancer patients may struggle to pay out-of-pocket expenses due to the high expenses incurred, the medical debt, or loss of work. Some cancer patients may face out-of-pocket costs of nearly $12,000 a year for one drug.

Insurance 273

Insurance Transportation Medical Medicine 273

World of DTC Marketing

MARCH 31, 2022

In 2014, researchers determined, 30% of insulin revenue went to middlemen. Researchers at USC found that drugmakers’ share of revenue from insulin sales has declined in recent years — and a more significant share is being siphoned off by pharmacy benefit managers, drugstores, wholesalers, and insurers. Los Angeles Times.

Insurance 240

Insurance Prescription Manufacturing Sales 240

World of DTC Marketing

DECEMBER 17, 2020

Another 8% said they or a family member put off treatment for a less serious condition, bringing the total percentage of households delaying care due to costs to 33%, tying the high from 2014. As 60 Minutes reported last weekend, one big chain, Sutter, has led to the most expensive childbirth in the U.S.

Healthcare 181

Healthcare Healthcare Government Physicians 181

Pharmaceutical Technology

SEPTEMBER 27, 2023

The idiopathic pulmonary fibrosis (IPF) market is underserved with just two licensed pharmaceutical treatments approved by the FDA in 2014.

Patients 105

Patients FDA Pharmaceutical Marketing 105

Pharmaceutical Commerce

JANUARY 15, 2024

FDA approves Keytruda (pembrolizumab) combined with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer, which is the 39th overall approved indication for the drug in the United States.

FDA 107

FDA Patients 107

World of DTC Marketing

SEPTEMBER 17, 2020

In 2019, 12 states had obesity rates in the highest category for this survey (35 percent or greater), a jump from three states in 2014, and nine in 2018. More recent state-level data from the 2019 Behavioral Risk Factor Surveillance System (BRFSS) confirm the trend that adult obesity rates continue to climb.

Healthcare 242

Healthcare Healthcare Insurance Healthcare Provider 242

European Pharmaceutical Review

FEBRUARY 28, 2025

For documents published in 2014 this number was just six; in 2024 it was 157 ( Figure 2 ). 2014-2024 (Credit: Elsevier BV – Scopus) Figure 2 : Documents by year. 2014-2024 (Credit: Elsevier BV – Scopus) Regionally, the US is dominating rare disease research. 1 Figure 1 : Documents by year.

Education 88

Education Patients Medicine Pharma 88

European Pharmaceutical Review

JANUARY 30, 2025

He joined Takeda as CEO in April 2014. Christophe Weber is set to retire as Chief Executive Officer (CEO) of Takeda in June 2026 after 12 years.Julie Kim, president of Takedas US Business Unit has been appointed as Webers successor. Weber is the companys current President, CEO and representative director.

Competition 59

Competition Marketing Management Leads 59

World of DTC Marketing

JANUARY 12, 2021

Recent Studies show that in 2014, 70% of the 50-65 age bracket use the internet, while 38% of those over 65 years old go online. For the first time, more than half of all online adults 65 and older (56%) use social media, Facebook in particular, according to Pew Research Center’s Social Media Update for 2014.

Patients 155

Patients Media Marketing Prescription 155

World of DTC Marketing

MAY 26, 2021

net revenue for Imbruvica has increased from $492 million in 2014 to $4.3 billion in Imbruvica net revenue from Medicare Part D between 2014 and 2018. AbbVie’s yearly U.S. net revenue from Humira more than tripled from $5.3 billion in 2013—the year it separated from Abbott—to $16.1 billion in 2020. billion in 2020. AbbVie’s U.S.

Competition 180

Competition Marketing Government Patients 180

PM360

MARCH 25, 2025

To see this years Talent & Diversity Fund winners please visit: [link] About The Creative Floor The Creative Floor Healthcare Awards was founded in 2014 by Shaheed Peera. We couldnt do it without you. The aim was to help change the way award shows are run.

Healthcare 52

Healthcare Healthcare 52

World of DTC Marketing

AUGUST 12, 2022

Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018. The most telling data on a disconnect between drug prices and research costs has received almost no public attention.

Pharma 255

Pharma Retail Pharmaceutical Pharmaceutical manufacturing 255

European Pharmaceutical Review

SEPTEMBER 12, 2023

The panelists referred to other documents that are useful for CCS development: the 2014 Pharmaceutical Healthcare Sciences Society (PHSS) Technical Monograph No 20 Bio-Contamination 2 as well as the Parenteral Drug Association (PDA) Technical Report 90: Contamination Control Strategy Development, 3 published in February 2023.

Consulting 128

Consulting Biopharma Manufacturing Pharmaceutical 128

Spotio

AUGUST 1, 2022

SPOTIO has been helping solar field sales take their teams to the next level and achieve more since 2014. The Complete Guide for Solar Sales Leaders. Today, we work with hundreds of residential and commercial solar companies worldwide.

Sales 98

Sales 98

World of DTC Marketing

SEPTEMBER 7, 2022

While that sounds encouraging, most cancer drugs launched between 2009 and 2014 cost more than USD 100,000 annually. COVID-19 has not impacted the number of launches in the oncology space, as 2020 and 2021 have seen similar rates of drug launches as in 2019.

Pharma 210

Pharma Food and Drug Administration Marketing Prescription 210

Pharmacy Times

JANUARY 15, 2024

The approval was based on the results of a phase 3 trial that found an improvement in progression-free survival among individuals treated with pembrolizumab.

FDA 49

FDA 49

pharmaphorum

NOVEMBER 29, 2022

At NeoImmuneTech, a Biotech company founded in Maryland, US, in 2014, the answer to this question looks straightforward: “We believe in incremental progress”, says Dr Se Hwan Yang, president and chief executive officer of the company. Dr Se Hwan Yang, PhD, President and Chief Executive Officer, founded NeoImmuneTech in January 2014.

Safety 105

Safety Patients Engineering Recruitment 105

European Pharmaceutical Review

NOVEMBER 2, 2022

The UK’s share of global research and development ( R&D ) investment has fallen by a fifth since 2014, according to recent data analysis by the Institute for Public Policy Research (IPPR). percent in 2014. percent GDP R&D investment. percent to 3.4 IPPR indicated that state investment drives private sector investment.

Government 98

Government Leads Manufacturing Medicine 98

pharmaphorum

NOVEMBER 27, 2022

. “If I had had that information at the beginning, I could have avoided the treatments I received that were never going to work,” added Stephen who was diagnosed with metastatic breast cancer in March 2014. “It would have saved me and the NHS a lot of money. It would have avoided false hope.”

Patients 104

Patients Medicine Government Leads 104

European Pharmaceutical Review

DECEMBER 12, 2024

Approval by the EC is significant because Elahere is the first new medication approved specifically for platinum-resistant ovarian cancer since 2014″ Approval by the EC is significant because Elahere is the first new medication approved specifically for platinum-resistant ovarian cancer since 2014 1 and it is the first novel therapy to demonstrate (..)

Medical 98

Medical Medicine Networking Pharmaceutical 98

World of DTC Marketing

AUGUST 31, 2022

” According to a 2014 study by the Intramural Research Program — a subsidiary of the National Institutes of Health—extreme obesity may shorten life expectancy by up to 14 years. . “Obesity rates among older Americans nearly doubled between 1988 and 2018, increasing from 22% to 40%.

Food 176

Food Government Leads Patients 176

Pharmaceutical Technology

JANUARY 22, 2023

Jardiance was initially approved in 2014 as a once-a-day tablet for use with diet and exercise to reduce blood sugar in type 2 diabetes adult patients. The company stated that the drug received Fast Track designation from the US FDA for the same indication in March 2020.

Food and Drug Administration 105

Food and Drug Administration FDA Food Patients 105

Pharmacy Times

MAY 20, 2024

In 2014, the cobas human papillomavirus test was approved by the FDA for first-line, primary screening in women aged 25 years and older.

FDA 52

FDA 52

Pharmacy Times

JANUARY 16, 2024

Previously, IgG-hyaluronidase recombinant was approved by the FDA in 2014 for the treatment of primary immunodeficiency in adult patients and has expanded to include some pediatric patients.

FDA 58

FDA Patients 58

European Pharmaceutical Review

NOVEMBER 2, 2022

The advanced facility will be based on the Regenerative Medicine Clinic established at Cedars-Sinai in 2014, developing clinical trials for neurological, cardiovascular, musculoskeletal and autoimmune diseases. The Cedars-Sinai Board of Governors Regenerative Medicine Institute and the Smidt Heart Institute will lead the project.

Food and Drug Administration 98

Food and Drug Administration Medicine Training Electronics 98

PharmExec

MARCH 13, 2024

Data shows that from 2014-2019, pneumococcal vaccinations in seniors increased by 10%, growing sales for Prevnar 13 due to government recommendation in addition to a high-profile advertising campaign.

Government 52

Government Pharmaceutical Sales 52

PharmExec

JANUARY 15, 2024

The FDA issued the 39th overall approval for Keytruda (pembrolizumab), with the latest in combination with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer.

FDA 52

FDA Patients 52

Pharmacy Times

NOVEMBER 11, 2022

Updated prescribing guidelines issued in 2014 and 2016 may explain lower use of opioids by 11.7% among patients with chronic, nonsurgical pain.

Patients 49

Patients 49

World of DTC Marketing

JUNE 5, 2021

From 2005 to 2014, most cancers associated with overweight and obesity increased in the United States, while cancers associated with other factors decreased. Breast (in women who have gone through menopause). Colon and rectum. Gallbladder. Upper stomach. Meningioma (a type of brain cancer). Multiple myeloma.

Government 193

Government Medicine Food Management 193

European Pharmaceutical Review

APRIL 29, 2024

Pfizer licensed BEQVEZ from Spark Therapeutics in December 2014. “A one-time treatment with BEQVEZ has the potential to be transformative for appropriate patients by reducing both the medical and treatment burden over the long term.” BEQVEZ is currently being reviewed by the European Medicines Agency (EMA), Pfizer confirmed.

Food and Drug Administration 96

Food and Drug Administration Medicine FDA Food 96

Pharmacy Times

DECEMBER 15, 2022

While the use of direct-acting antiviral treatment for hepatitis C virus increased from 2014 to 2018, treatment rates have declined since 2019 and remain suboptimal.

49

49

pharmaphorum

OCTOBER 3, 2022

Translarna has had European approval for usage since 2014 and has also been available under terms similar to the MAA to DMD patients in Scotland since 2021. Last week, Sarepta Therapeutics filed for accelerated FDA approval of its DMD gene therapy developed with Roche, SRP-9001 (delandistrogene moxeparvovec).

Patients 98

Patients Medicine FDA Management 98